Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs Kyntra Bio Inc (KYNB)

Adaptimmune Therapeutics PLC and Kyntra Bio Inc are both Biotechnology companies. Adaptimmune Therapeutics PLC and Kyntra Bio Inc are of similar size ($14.8M and $14.6M). Adaptimmune Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Kyntra Bio Inc trades at 0.1×. Kyntra Bio Inc grew revenue faster over the last twelve months: −37.2% against −54.0%. Kyntra Bio Inc has the higher net margin (3,967.8% vs −262.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Adaptimmune Therapeutics PLC leads on 8 and Kyntra Bio Inc on 8.

Valuation

Metric ADAPY KYNB Biotechnology median
P/E n/m 0.08 10.60
P/S 0.08 3.37 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 0.08 15.46 9.02
Earnings yield (3,250.00%) 1,179.69% (32.88%)
Free cash flow yield (3,648.13%) (245.05%) (23.13%)

Profitability

Metric ADAPY KYNB Biotechnology median
Gross margin 94.81% 6.28% 68.51%
Operating margin (427.75%) (1,089.78%) 0.00%
Net margin (262.46%) 3,967.77% 0.00%
Free cash flow margin (294.49%) (824.19%) 0.00%
Return on equity (1,349.52%) (157.83%) (51.96%)
Return on assets 0.00% 131.26% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY KYNB Biotechnology median
Revenue growth (TTM) (53.99%) (37.15%) 6.76%
EPS growth (last fiscal year) 142.86% 478.08% 29.88%
Revenue growth, 5-year CAGR 8.40% (48.42%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY KYNB Biotechnology median
Debt to equity (0.36) 0.00 0.00
Current ratio 1.52 2.69 4.97
Net debt to EBITDA 0.47 1.97 1.01

Dividend

Metric ADAPY KYNB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ADAPY KYNB Biotechnology median
Market cap 14.55m 14.82m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack